Authors
Latest:
Advancing COPD Research: Harnessing Wearable Sensors and Remote Monitoring for Improved InsightsWearable sensors and remote monitoring technology can help HCPs monitor and manage COPD more effectively.
Latest:
FDA’s New Accelerated Approval Draft GuidanceWhat biopharma companies need to know about this evolving regulatory pathway.
Latest:
2025 Pipeline Report: The Edge of Greatness?Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five expanding therapeutic areas.
Latest:
Recent Federal Circuit Developments in Patent LicensingUnderstanding of recent legal developments can help companies avoid infringement.
Latest:
AI: A Value Advantage? Maximizing Your Brand OutreachPractical ways product teams can leverage the benefits of generative artificial intelligence as a strategic advantage in pharmaceutical and life sciences commercialization.
Latest:
From 1990s Business Wisdom to Today’s BioPharma SuccessApplying the McKinsey 7S Framework to TLL and regional marketing teams.
Latest:
Pharma and AI: 2021 and BeyondFerdi Steinmann looks at pharma's current relationship with AI and how it is set to evolve.
Latest:
Bringing Biosimilars to Market in EuropeIf the life sciences sector can support healthcare professionals to gain confidence in substituting original treatments with new biosimilars, prices will reduce and patient outcomes will be enhanced.
Latest:
Beyond Approval: Why Your Oncology Label Determines Commercial SuccessThe stakes have never been higher.
Latest:
Viable Options: Packaging and Partnering for Successful Storage and Transport of Conventional Cold-Chain Vaccines for Covid-19***Live: Thursday, February 25, 2021 at 11am EST | 8am PST | 4pm GMT | 5pm CET*** As strategic planning among manufacturers and logistics partners commences, this webinar will serve as a platform to discuss service offerings and explore the most effective possible solutions. *** On demand until Feb. 25, 2022***
Latest:
FDA Inspection and Enforcement Developments During the COVID-19 PandemicMitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations.
Latest:
Remembering That TIME Magazine Issue; Celebrating Progress in Patient EngagementLooking to the past reminds industry of great strides taken in clinical research for patients.
Latest:
The View From the ForefrontMatthew Howes, President at Greater Than One, discusses what to expect in the next twelve months in healthcare marketing.
Latest:
The Recipe for Relief: Overcoming Industry Pain PointsWhy investing in people and training can help drugmakers deal with six pressing challenges in particular in the year ahead.
Latest:
Empowering Prior Authorization ProfessionalsA look at the rise of prior authorization certified specialists (PACS)—and their value in improving patient access and outcomes.
Latest:
Don’t Waste A Crisis: How Paratek is Navigating the Business Implications of the COVID-19 PandemicA look at how pharmaceutical company, Paratek is navigating the launch of a new antibiotic during the COVID-19 pandemic.
Latest:
‘Selling a Vision’: Today’s Playbook for StartupsThe Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.
Latest:
Beyond Medicines: Pharma's Journey with Patient Family Advisory CouncilsIncluding patient and family feedback in our discussions will help shape our understanding of their perception of provided care and services and how we operate as a whole.
Latest:
New Technologies Come with New Litigation RisksCybersecurity vulnerabilities embedded in AI and machine learning pose significant litigation risks as life sciences companies move to digital technologies.
Latest:
The Untapped Potential of Behavioral Science in Medical AffairsHistorically, Medical Affairs teams have relied on reporting only empirical evidence such as efficacy and tolerability profiles to influence uptake of a new drug or therapy. Here, Ben Routley and Mark Pringle explore the scope for applying behavioral science techniques to improve the impact of client communications.
Latest:
As Pharma Continues to Adapt to AI, the POSA Standard will Need to Equally AdaptU.S. patent law will have to adapt to the use of AI in the life sciences industry.
Latest:
AI Built for Pharma: Why Out-of-the-Box Beats Build-From-ScratchWebinar Date/Time: Mon, Jul 28, 2025 11:00 AM EDT
Latest:
Comparing Three Common Pharma Communication AvenuesPavel Klymenko, Head of Omnichannel at Viseven, compares three top approaches to pharma communication and elucidates which are here to stay.
Latest:
Herspiegel Consulting Dives Into the Value NarrativeKapil Raina, MD, Principal of Market Access at Herspiegel Consulting, talks about disconnects in the industry, how patients have easier access to healthcare information, and the exciting future of pharmaceutical manufacturing and patient care.
Latest:
Final ThoughtsThe future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
